Labeling mishaps spark separate recalls

A questionable four-month stretch on a packaging line last year led to two recalls by Upsher-Smith last week. Packaging troubles led also to a recall by Qualitest.

The first of Upsher-Smith's recall notices came last Wednesday and concerned one lot of mislabeled Jantoven warfarin sodium. The tip-off came from a retail pharmacist, who identified 10-mg tablets in a bottle labeled with the 3-mg dosage.

The second notice came Friday and expanded the action to additional drugs packaged on the same line and in the same timeframe as the warfarin, May through November, 2010. Friday's action, a precautionary measure, involves six additional products: Amantadine, Amlodipine, Androxy, Baclofen, Bethanechol and Oxybutynin.

Upsher-Smith says its investigation so far points to an isolated incident and it has already taken corrective measures.

Earlier this month, Qualitest announced a recall when a bottle of hydrocodone bitartrate and acetaminophen tablets was found labeled as phenobarbital. Two additional lots used the same label stock and may be affected, the company says.

- here's Upsher-Smith's expanded recall notice
- see the Qualitest notice

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.